Sugi Predict

Sugi Predict / Compounds / SCHEMBL2482267

SCHEMBL2482267

SCHEMBL2482267

CO[C@H](CO)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.53
▸ TRPA1 O75762 5/20 0.45
▸ KMT2A Q03164 2/20 0.42
▸ LMNA P02545 1/20 0.41
▸ SLC6A4 P31645 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ SLC6A2 P23975 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ AOC3 Q16853 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ BLM P54132 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL872713 1.00 GSR (0.53) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL2064318 1.00 GSR (0.53) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL11039776 0.89 GSR (0.49) GSRKMT2ALMNATSHRSLC6A2
SCHEMBL10422453 0.88 PTGS2 (0.44) GSRSLC6A4SLC6A2CYP3A4CYP2D6
SCHEMBL12530561 0.83 TRPA1 (0.48) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL1832901 0.83 TRPA1 (0.48) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL9245144 0.82 TRPA1 (0.43) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL10755600 0.82 TRPA1 (0.43) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL6343043 0.81 SLC6A4 (0.41) GSRTRPA1KMT2ALMNASLC6A4
SCHEMBL4426985 0.81 GSR (0.57) GSRTRPA1LMNASLC6A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3649183-A1 SILICONE COMPOUNDS The Procter and Gamble Company (US) 2020-05-13 — — EP claimed
EP-3649184-A1 SILICONE COMPOUNDS The Procter and Gamble Company (US) 2020-05-13 — — EP claimed
WO-2019010263-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2019-01-10 — — WO claimed
WO-2019010265-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2019-01-10 — — WO claimed
US-11230557-B2 mTORC modulators and uses thereof AEOVIAN PHARMACEUTICALS, INC. (US) 2022-01-25 — — US disclosed
US-11021492-B2 mTORC modulators and uses thereof AEOVIAN PHARMACEUTICALS, INC. (US) 2021-06-01 — — US disclosed
US-20210008041-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2021-01-14 — — US disclosed
US-20210002300-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2021-01-07 — — US disclosed
WO-2020154447-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2020-07-30 — — WO disclosed
EP-3649184-A1 SILICONE COMPOUNDS The Procter and Gamble Company (US) 2020-05-13 — — EP disclosed
EP-3649183-A1 SILICONE COMPOUNDS The Procter and Gamble Company (US) 2020-05-13 — — EP disclosed
US-10472374-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-11-12 — — US disclosed
EP-2376894-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS The Lubrizol Corporation (US) 2011-10-19 — — EP disclosed
EP-2373977-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS The Lubrizol Corporation (US) 2011-10-12 — — EP disclosed
WO-2010077753-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS THE LUBRIZOL CORPORATION (US) 2010-07-08 — — WO disclosed
WO-2010077754-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS THE LUBRIZOL CORPORATION (US) 2010-07-08 — — WO disclosed
WO-2003070239-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-08-28 — — WO disclosed
US-5494923-A Method of ameliorating cerebral circulation BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-02-27 — — US disclosed
US-5444077-A Ameliorant of cerebral circulation and optical isomer of NB-818, processes for its use BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-22 — — US disclosed
EP-0311053-A2 Ameliorant of cerebral circulation and optical isomer of nb-818, processes for its production and its use BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008041-A1 MTORC MODULATORS AND USES THEREOF MTOR, RICTOR, RPTOR GSR 2701/4885TRPA1 4691/4885KMT2A 3291/4885
US-11230557-B2 mTORC modulators and uses thereof MTOR, RICTOR, RPTOR GSR 2701/4885TRPA1 4691/4885KMT2A 3291/4885
US-10472374-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 GSR 1846/4885TRPA1 4839/4885KMT2A 2071/4885
US-20210002300-A1 MTORC MODULATORS AND USES THEREOF MTOR, RICTOR, RPTOR GSR 2701/4885TRPA1 4691/4885KMT2A 3291/4885
US-11021492-B2 mTORC modulators and uses thereof MTOR, RICTOR, RPTOR GSR 2701/4885TRPA1 4691/4885KMT2A 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.